J 2017

The joint EPUAP & EWMA pressure ulcer prevention & patient safety advocacy project

MOORE, Z., J.V. SORIANO, Andrea POKORNÁ, L. SCHOONHOVEN, H. VUAGNAT et. al.

Základní údaje

Originální název

The joint EPUAP & EWMA pressure ulcer prevention & patient safety advocacy project

Autoři

MOORE, Z. (372 Irsko), J.V. SORIANO (724 Španělsko), Andrea POKORNÁ (203 Česká republika, garant, domácí), L. SCHOONHOVEN (840 Spojené státy), H. VUAGNAT (756 Švýcarsko), A. MARKOVA (826 Velká Británie a Severní Irsko) a J. KRISTENSEN (826 Velká Británie a Severní Irsko)

Vydání

Wounds UK, London, Wounds UK Ltd. 2017, 1746-6814

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30307 Nursing

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Kód RIV

RIV/00216224:14110/17:00098409

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

EPUAP; EWMA; Key performance indicator; Patient safety; Pressure ulcer

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 22. 3. 2018 15:47, Soňa Böhmová

Anotace

V originále

Background: Pressure ulcers (PUs) are a common, costly, debilitating problem across all healthcare sectors, despite significant investment in education and training and use of human resources, equipment, and technological advancements. In recognising the persistent problem of PUs, the European Wound Management Association (EWMA) and the European Pressure Ulcer Advisory Panel (EPUAP) have created a group to work collectively on a specific project advocating for the prevention of PUs to be considered as a major health care and patient safety issue. Aim: The overall aim of the project is to establish a joint EPUAP-EWMA working group on PU prevention and engage in patient safety agendas at the European level as well as at the national level in selected European countries. Discussion: We are seeking to place prevention of PUs as a high priority on the patient safety agenda within the European Union (EU). To achieve this, given the lack of agreed methodology for incidence monitoring, we advocate for the use of standardised monitoring of PU prevalence, with targeted prevention measures to reduce prevalence, made available across the continuum of care. Conclusion: Adopting PU prevalence as a key measurement tool across the wider health care sector in the EU, will ensure that both adequate monitoring of prevalence and use of prevention can be achieved.